TRexBio closes IPO raising $116.7 million on Nasdaq

1 min read | Published on 14 Oct 2026, 02:32 AM |Updated on 14 Oct 2026, 02:32 AM

Reviewed by

Shraddha JScanX News Team

Add as a preferred
source on Google

Key Highlights

TRexBio closed its IPO selling 8,333,334 shares at $14.00 each
Gross proceeds totaled approximately $116.7 million before expenses
All shares were sold by the company, not existing shareholders
Listing commenced on Nasdaq Global Select Market under ticker TRXB

*this image is generated using AI for illustrative purposes only.

TRex Bio, Inc. (NASDAQ: TRXB) announced the closing of its initial public offering, securing approximately $116.7 million in gross proceeds. The clinical-stage biotechnology company sold 8,333,334 shares of common stock at a price of $14.00 per share.

All shares in the offering were sold by the company itself. The transaction marks the completion of the public listing for TRexBio, which focuses on tissue Treg biology for immunoregulatory medicines. The stock is listed on the Nasdaq Global Select Market under the ticker symbol "TRXB".

Offering details and banking syndicate

The aggregate gross proceeds were calculated before deducting underwriting discounts, commissions, and other offering expenses. The offering was made only by means of a prospectus, with a registration statement filed with the U.S. Securities and Exchange Commission becoming effective on October 8, 2026.

The following firms acted as lead book-running managers for the offering:

J.P. Morgan
Evercore ISI
Cantor
Stifel

Wedbush PacGrow served as the book-running manager.

Company profile and strategic focus

TRexBio is headquartered in South San Francisco, California. The company is dedicated to the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair. Its primary therapeutic focus addresses unmet needs in patients with autoimmune and inflammatory diseases.

The company utilizes its Deep Biology Platform to decode Treg functionality in human tissue. This platform maps key drivers of immune dysregulation to uncover novel targets and insights that inform drug discovery and translational efforts. These efforts have generated multiple therapeutic development candidates across TRexBio’s wholly owned pipeline and through collaborations with leading pharmaceutical partners.

What the numbers show

The pricing at $14.00 per share resulted in a total valuation for this tranche of approximately $116.7 million. The structure of the deal, where all shares were sold by TRexBio rather than existing shareholders, indicates that the entire capital raised flows directly into the company's balance sheet to fund operations and research, rather than providing liquidity to early investors.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

How will the $116.7 million in net proceeds specifically allocate between advancing lead clinical candidates and expanding the Deep Biology Platform's target discovery capabilities?

What are the projected timelines for TRexBio to initiate Phase 1 clinical trials for its most advanced immunoregulatory candidates using the newly raised capital?

How might the successful IPO and institutional backing from firms like J.P. Morgan and Evercore ISI influence future partnership valuations with major pharmaceutical companies?